Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Before leaving, you will be provided with detailed aftercare instructions to follow, ensuring you achieve the best possible results from your treatment
The LEADER trial with liraglutide and the SUSTAIN-6 trial with semaglutide demonstrated cardiovascular benefits that may be partially mediated through anti-inflammatory mechanisms
Both the Kidney Disease Improving Global Outcomes guidelines and American Diabetes Association Standards of Care recommend GLP1-RA as the preferred glucose lowering class for people with T2D and moderate to advanced CKD or ESRD because of their demonstrated cardiovascular benefits in people with T2D at high risk of cardiovascular disease, which includes CKD 13,14
1 2 3 "UpToDate: Alcohol intake and pregnancy"
.png)
